Nick Bryant


Authored Items

FDA Streamlines Expanded Access Application for Patients to Get Investigational Drugs

July 2016, Vol 7, No 6 - Health Policy

The Individual Patient Expanded Access Application, which is designed to streamline the application procedure for individual patients who apply for expanded access to investigational therapeutics, including expanded access to drugs that are not in clinical trials, was recently updated by the FDA. Form FDA 3926 authorizes expanded access to investigational drugs for patients with serious or life-threatening conditions who have no therapeutic options. [ Read More ]

Are We Making Progress in Acute Myeloid Leukemia?

November 2016, Vol 7, No 10 - NCCN Hematologic Cancers Highlights

New York, NY—Acute myeloid leukemia (AML) was a hot topic at the 2016 National Comprehensive Cancer Network (NCCN) Congress on Hematologic Malignancies. Jessica K. Altman, MD, Associate Professor of Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, assured attendees that time was not standing still for patients with AML. [ Read More ]

Rethinking Radiotherapy for Early-Stage Hodgkin Lymphoma

November 2016, Vol 7, No 10 - NCCN Hematologic Cancers Highlights

New York, NY—In a presentation at the 2016 National Comprehensive Cancer Network (NCCN) Congress on Hematologic Malignancies, Ranjana H. Advani, MD, Saul Rosenberg Professor of Lymphoma, Stanford University Medical Center, CA, and Vice Chair of the NCCN’s non-Hodgkin and Hodg­kin lymphoma guidelines panel questioned the necessity of using radiotherapy in patients with stage I or stage II Hodgkin lymphoma. [ Read More ]

Shifting Treatment Paradigms for Multiple Myeloma

November 2016, Vol 7, No 10 - NCCN Hematologic Cancers Highlights

New York, NY—How to integrate the many new drugs recently approved for multiple myeloma into clinical practice was a topic addressed by Carol Ann Huff, MD, Director of the Myeloma Program at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, at the 2016 National Comprehensive Cancer Network (NCCN) Congress on Hematologic Malignancies. [ Read More ]

NCCN Unveils New Clinical Guidelines for Myelofibrosis

November 2016, Vol 7, No 10 - NCCN Hematologic Cancers Highlights

New York, NY—Myeloproliferative neoplasms (MPNs) include myelofibrosis, polycythemia vera, and essential thrombocytopenia, and affect an estimated 295,00 individuals in the United States. MPNs represent a diverse array of diseases. This has led to the generation of various treatment guidelines that are often contradictory and difficult to interpret. However, the National Comprehensive Cancer Network (NCCN) is developing a unified field theory on the diagnosis and treatment of MPNs. [ Read More ]